Elanco Animal Health Inc 4

EVP and CFO Robert M. VanHimbergen received a routine deferred stock unit award equivalent to about 8.22 shares of Elanco Animal Health Inc. common stock.

On August 21, 2026, Elanco Animal Health Inc. EVP and CFO Robert M. VanHimbergen received a small grant of deferred stock units under the company’s Executive Deferral and Stock Match Plan, representing approximately 8.22 units that correspond economically to the company’s common stock at an implied reference price of about $23.97 per share (totaling roughly $197). These deferred stock units entitle the holder to receive either cash or an equivalent number of Elanco common shares following termination of employment or in a specified future year, and therefore function as a form of deferred compensation rather than an open-market purchase or sale. The filing also reflects 8.2194 corresponding common shares credited in derivative form, resulting in post-transaction derivative ownership of about 141.8242 units classified as directly held; using the current stock price, this deferred stake is modest in value and appears to be routine compensation rather than a signal-driven insider trade.

Filing Facts

CIK

1739104

Ticker

ELAN

Form

4

Source Type

fda

Accession

0001724169-26-000039

Alert Tier

4